Log in to search using one of your social media accounts:

 

Mesothelioma Clinical Trials Involve Gene Therapy
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - September 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news

Global Mesothelioma Deaths Remain High Despite Poor Data
An estimated 38,400 people around the world will die this year from mesothelioma cancer, according to a report recently published in Occupational & Environmental Medicine. The estimation by the international peer-reviewed journal included 230 countries. Data used for the study came from the World Health Organization’s (WHO) Mortality Database and extrapolated information based on gender- and age-specific death rates. “The global burden of mesothelioma is real,” Dr. Ken Takahashi, director of Asbestos Diseases Research Institute, University of Sydney Gate 3, Australia, told Asbestos.com. “It is v...
Source: Asbestos and Mesothelioma News - September 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Asbestos Diseases Research Institute asbestos-related lung cancer Australia mesothelioma Bangladesh Dr. Christina Fitzmaurice Dr. Ken Takahashi Global Burden of Disease Mesothelioma death rate mesothelioma latency period mesothelioma uni Source Type: news

MD Anderson Retains Top Spot for Cancer Care
U.S. News & World Report ranked the MD Anderson Cancer Center in Houston the No. 1 cancer care hospital in America for the third consecutive year. MD Anderson has been a leader in the treatment of pleural mesothelioma, a contributing factor in maintaining its top billing on the rankings. Memorial Sloan Kettering in New York and Mayo Clinic in Rochester, Minnesota, were No. 2 and No. 3, respectively, in the 2017-18 Best Hospitals for Cancer  listing. U.S. News & World Report — a global authority in hospital care — has published the rankings annually for 28 years, helping patients make tough health c...
Source: Asbestos and Mesothelioma News - September 6, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Barnes-Jewis Hospital best mesothelioma cancer centers Cardiology Cleveland Clinic Gastroenterology H. Lee Moffitt Cancer Center and Research Institute heart surgery Johns Hopkins Massachusetts General Hospital Mayo Clinic Mayo Clinic- Source Type: news

Mesothelioma Patients Survive Longer with Trimodal Treatment
Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote...
Source: Asbestos and Mesothelioma News - September 5, 2017 Category: Environmental Health Authors: Matt Mauney Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news

Upcoming Mesothelioma Symposium Filled with Hope
Discussions About Immunotherapy for Mesothelioma Cameron also will speak about engineering mesenchymal stem cells for immunotherapy. Clare Cameron, who is the executive director of the Pacific Mesothelioma Center (PMC) and not related to Dr. Robert Cameron, will talk about resources for research. Lein Hua-Feng, a nurse practitioner at PMC, will discuss the benefits of caregiver support groups. “The symposium will provide an unrivaled opportunity for both the medically savvy and general public, including mesothelioma patients,” Clare Cameron said. “You’ll hear about the most promising medical advance...
Source: Asbestos and Mesothelioma News - August 29, 2017 Category: Environmental Health Authors: Matt Mauney Tags: 7th annual International Symposium on Mesothelioma Angiogenesis Inhibition and Chemotherapy Arti Shukia Banaras Hindu University bap1 Center at the University Hospital of Siena clare cameron Dr. Anna Nowak Dr. Brian Cunniff Dr. David Sch Source Type: news

Trump ’ s Halt on Coal Mining Study Has Asbestos Implications
The U.S. Department of the Interior has ordered a halt to a study on the public health risks of mountaintop removal mining in Appalachia — an area ripe with natural asbestos deposits. A letter from the Interior Department on Monday directed the National Academies of Sciences, Engineering and Medicine to “cease all work” on the study, citing responsible spending of taxpayer dollars as the reason for the decision. The $1 million National Academies study began in 2016 and was expected to take two years to complete. It aimed to evaluate health risks of a common mining technique for people living near surfac...
Source: Asbestos and Mesothelioma News - August 24, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Appalachian Mountains arsenic asbestos exposure Appalachia asbestos exposure coal mining asbestosis coal mining Bill Price Central Appalachia coal mining Appalachia Donald Trump Environmental Health Perspectives Glenda Owens House Co Source Type: news

Alternative Medicine Alone Leads to Lower Cancer Survival
Cancer patients who opt for alternative therapy instead of conventional medicine significantly decrease their chances of survival, according to researchers at Yale School of Medicine. Although the popularity of alternative medicine continues to grow, a recent study published in the Journal of the National Cancer Institute found survival rates significantly reduced for those who use it as first-line therapy. Conventional cancer treatments — chemotherapy, surgery and radiation — still produce a much better chance of survival. Mesothelioma was not included in the study, but the findings are relevant to this rare ...
Source: Asbestos and Mesothelioma News - August 23, 2017 Category: Environmental Health Authors: Matt Mauney Tags: acupuncture cancer Alternative medicine alternative mesothelioma treatment alternative therapy survival alternative vs conventional medicine breast cancer colon cancer Conventional cancer treatments Dr. David Gorski Dr. Skyler Johnson Source Type: news

Nearly One-Third of Mesothelioma Patients Remain Untreated
A new report from the National Cancer Institute (NCI) shows between 20 and 30 percent of malignant mesothelioma patients do not receive any cancer treatment. The study, “Patterns of care and survival among patients with malignant mesothelioma in the United States,” published August 10 in the journal Lung Cancer, aimed to describe the patterns of care and subsequent survival among mesothelioma patients in the U.S. while adjusting for patient demographics and pre-existing health conditions. Using the NCI’s Surveillance, Epidemiology, and End Results (SEER) data, researchers discovered significant differenc...
Source: Asbestos and Mesothelioma News - August 21, 2017 Category: Environmental Health Authors: Matt Mauney Tags: amount of mesothelioma patients eligible for surgery checkpoint inhibitors clinical trial enrollment cytoreduction surgery heated chemotherapy pleural mesothelioma heated intraperitoneal chemotherapy immunotherapy mesothelioma keytruda Lin Source Type: news

Mesothelioma, Asbestos Diseases Costly for Canadians
The annual cost of asbestos-related occupational disease in Canada is estimated at $2.35 billion, according to new findings by a panel of epidemiologists, public health experts and medical professionals. Their estimate is based on direct, indirect and quality-of-life costs related to the 2,331 patients in Canada diagnosed with mesothelioma or asbestos-related lung cancer in 2011. Occupational and Environmental Medicine, a monthly peer-reviewed medical journal, released the updated report in July. It followed a similar study conducted by the same group of experts in 2016. “When you look at the big picture [and] consid...
Source: Asbestos and Mesothelioma News - August 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: asbestos ban in canada asbestos mines canada asbestosis canada canada mesothelioma Dr. Emile Tompa economic burden asbestos canada financial burden mesothelioma canada health care costs mesothelioma canada House of Commons Occupational a Source Type: news

Lung-Sparing P/D Surgery Best for Mesothelioma Patients
The latest studies have shown, and most thoracic oncologists agree, that lung-sparing pleurectomy/decortication is a better surgical option for mesothelioma patients today than the more aggressive extrapleural pneumonectomy. Less is better. Quality of life becomes better, too. “In most instances, the pleurectomy/decortication is the operation of choice now,” thoracic surgeon Dr. Andrea Wolf at Mount Sinai Hospital in New York City, told Asbestos.com. “We’re finding that patients just do better in terms of survival and in terms of quality of life.” Wolf recently co-authored “The impact of...
Source: Asbestos and Mesothelioma News - August 9, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Annals of Translational Medicine best surgery for mesothelioma Dr. Andrea Wolf Dr. Hasan Batirel eligible for mesothelioma surgery extrapleural pneumonectomy lung-sparing surgery Marmara University Hospital mesothelioma histology mesothe Source Type: news

Promising Drug Reduces Growth of Aggressive Mesothelioma
Scientists in Italy have found a platinum-based drug that successfully lessens growth of the most aggressive type of mesothelioma cancer cells. Researchers at the University of Salento discovered the experimental drug Ptac2S was more effective in reducing the spread of sarcomatoid malignant pleural mesothelioma cells in mice compared to cisplatin — the most widely used chemotherapy drug for treating mesothelioma. Sarcomatoid is the least common of the three mesothelioma cell types but is considered more aggressive and harder to treat. A diagnosis with the sarcomatoid cell type is typically associated with a poor pro...
Source: Asbestos and Mesothelioma News - August 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Alimta alternatives to cisplatin Antonella Muscella Biphasic mesothelioma chemotherapy for mesothelioma chemotherapy resistance DNA adducts epithelioid mesothelioma genomic activities mesothelioma clinical trials mesothelioma survival Source Type: news

Bayer ’ s Drug Failed to Improve Mesothelioma Survival
Drug manufacturers announced disappointing ends recently to two different clinical trials involving pleural mesothelioma, dampening earlier enthusiasm over the promise of immunotherapy. Anetumab ravtansine, manufactured by Bayer, and tremelimumab, from drugmaker AstraZeneca, failed an effectiveness test as a stand-alone, second-line treatment for mesothelioma, according to both manufacturers. “Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, an executive vice president at Bayer. Although trial officials have not released ...
Source: Asbestos and Mesothelioma News - July 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: anetumab ravtansine astrazeneca cancer drug bayer cancer drug bayer mesothelioma drug mesothelioma clinical trials tremelimumab Source Type: news

Pigment Found in Chamomile, Parsley Kills Mesothelioma Cells
A yellowish pigment common to parsley, celery, chamomile tea, oranges and grapefruit may be the latest treatment for mesothelioma cancer, a new study shows. While numerous studies have demonstrated the anti-cancer and antioxidant properties of apigenin (API), the natural pigment found in these plants and vegetables, researchers recently tested it against malignant mesothelioma cells. Doctors at the University of Rome evaluated the anti-tumor activities of API in mice injected with mesothelioma cells. API inhibited malignant mesothelioma (MM) cell survival and activated cell death, known as apoptosis. Mice treated with AP...
Source: Asbestos and Mesothelioma News - July 26, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: apigenin benefits apigenin for cancer apigenin for mesothelioma new mesothelioma treatment Source Type: news

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

Asbestos Found in Children ’ s Makeup
Justice, a national retail chain marketed to young girls, has stopped selling a cosmetics product after discovering it contained talc contaminated with asbestos fibers. The government-licensed Scientific Analytical Institute (SAI) in Greensboro, North Carolina, confirmed the asbestos contamination after testing the product as part of a Durham-based WTVD-TV news investigation. The tainted product was Just Shine Shimmer Powder, which the company stopped selling at stores and removed from its website, according to a Tuesday post on its Facebook page. “Our suppliers are required to produce all products in compliance wit...
Source: Asbestos and Mesothelioma News - July 19, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos contaminates makeup asbestos in children's makeup asbestos in makeup asbestos in products asbestos in talcum powder asbestos in toys makeup with asbestos Source Type: news

Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.&rdqu...
Source: Asbestos and Mesothelioma News - July 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center Aduro Biotech CRS-207 Dr. Tawee Tanvetyanon FDA approval Keytruda improving mesothelioma prognosis Merck mesothelioma chemotherapy mesothelioma clinical trials mesothelioma immunotherapy moffitt cancer center m Source Type: news

Asbestos Type Has No Effect on Mesothelioma Latency Period
New research from scientists in Germany sheds more light on the unusually long latency period associated with mesothelioma and other asbestos-related diseases. The study, published earlier this year in the European Respiratory Journal, is the first to track the presence of asbestos fibers in lung tissue over time. Mesothelioma has one of the longest latency periods of any cancer. It typically takes anywhere from 20 to 50 years after a person’s initial exposure to asbestos before symptoms arise. Using the German Mesothelioma Register, researchers at Ruhr-University Bochum discovered the volume of asbestos fibers in...
Source: Asbestos and Mesothelioma News - July 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: amosite amphibole asbestos exposure asbestos fiber burden asbestos fibers in lungs biopersistence of asbestos bronchoalveolar lavage Chrysotile asbestos Chrysotile asbestos fibers European Respiratory Journal German Mesothelioma Regist Source Type: news

SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news

BAP1 Mesothelioma Mutation Focus of Upcoming Clinical Trial
Researchers at the University of Hawaii believe they are close to a fix for the genetic mutation that makes certain people more susceptible to developing mesothelioma cancer and more resistant to chemotherapy. Dr. Michele Carbone, director of thoracic oncology at the UH Cancer Center, said the BAP1 genetic mutation his research first uncovered in 2011 will be key to future prevention and treatment of mesothelioma. “I do not like to make promises,” Carbone told Asbestos.com. “But our record shows that we’ve always delivered more than we planned for. We have a pretty good idea how to fix it.” Hi...
Source: Asbestos and Mesothelioma News - July 5, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bap1 gene mutation doctor michele carbone gene therapy for mesothelioma mesothelioma clinical trial university of hawaii cancer center Source Type: news

Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial
The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma. The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials. “We have every reason to believe it will be effective with mesothelioma, too,” Dr. Bernardo Goulart, chief trial investigator and medical oncologist at t...
Source: Asbestos and Mesothelioma News - June 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: cancer in seattle doctor Bernardo Goulart mesothelioma clinical trials mesothelioma in seattle mesothelioma treatment seattle cancer care alliance Source Type: news

Time Between Surgeries Helps Predict Mesothelioma Survival
A new study from researchers at the City of Hope cancer center in Los Angeles and Wake Forest University School of Medicine in Winston-Salem, North Carolina, reveals how the length of time between initial and follow-up cytoreduction surgery and HIPEC plays a role in patient survival. The study, published in June in the Journal of Surgical Oncology, shows peritoneal mesothelioma patients who repeat the procedure between one and two years after the initial surgery have the most favorable outcome, with a median overall survival of nearly four years. Peritoneal mesothelioma is an aggressive, asbestos-related cancer, and recu...
Source: Asbestos and Mesothelioma News - June 23, 2017 Category: Environmental Health Authors: Matt Mauney Tags: appendiceal cancer city of hope cancer center colon cancer cytoreduction surgery debulking surgery Dr. Konstantinos Votanopoulos gastrointestinal cancer heated intraperitoneal chemotherapy HIPEC Journal of Surgical Oncology moffitt can Source Type: news

Can a Breath Test Diagnose Mesothelioma in the Early Stages?
Much of mesothelioma research centers on identifying new and noninvasive biomarkers for earlier detection of the asbestos-related cancer. Progress has been made in finding biomarkers in blood and pleural effusions, but researchers in Belgium now believe the next breakthrough in early diagnosis for mesothelioma cancer may be a breath test. Researchers at Ghent University Hospital and Antwerp University Hospital recently highlighted the potential of breath analysis, called breathomics, as a noninvasive screening tool for malignant pleural mesothelioma. The Oncotarget medical journal published the study in May. Breath tests...
Source: Asbestos and Mesothelioma News - June 20, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Antwerp University Hospital biomarkers breath tests biomarkers for mesothelioma biopsies mesothelioma breath analysis mesothelioma breath test mesothelioma breathomics chromatography-mass spectrometry early detection of mesothelioma elec Source Type: news

Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - June 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news

How Math Is Reshaping Mesothelioma Chemotherapy
This study demonstrates the feasibility of this approach since both preliminary encouraging signs of activity and no unexpected toxicities were observed, in this heavily pre-treated patients’ population.” Study Size and Rarity of Mesothelioma Present Challenges As a phase I clinical trial, it is a novel approach at this point but a promising step for future chemotherapy treatment plan protocols. The limited number of patients in the study — nine NSCLC and three mesothelioma — is also problematic, but the planned second phase of the study will include the new model’s effect on the immune syste...
Source: Asbestos and Mesothelioma News - June 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Aix-Marseille University anemia chemotherapy best vinorelbine regimen chemotherapy side effects Fabrice Barlesi low-dose oral chemotherapy drugs math cancer chemotherapy math to fight cancer mathematical modeling cancer mesothelioma chem Source Type: news

Chemotherapy Mix Doubles Peritoneal Mesothelioma Survival
Surgeon Paul Sugarbaker at the Washington Cancer Institute has nearly doubled the five-year survival rate for patients with peritoneal mesothelioma by adding long-term regional chemotherapy to his already groundbreaking protocol. Sugarbaker, a pioneer in advancing peritoneal mesothelioma treatment for more than two decades, believes this latest development could have far-reaching implications. “This could be a game changer,” Sugarbaker told Asbestos.com. “The reaction has been, ‘Wow! [It’s] hard to believe.’ We’ve got to exploit this [advancement] as best as we can.” Sugarbak...
Source: Asbestos and Mesothelioma News - June 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: cytoreductive surgery epithelioid cell type European Journal of Surgical Oncology HIPEC hyperthermic perioperative chemotherapy International Journal of Hyperthermia intraperitoneal chemotherapy long-term regional chemotherapy MedStar Wash Source Type: news

Using Viruses to Boost Mesothelioma Immunotherapy
Immunotherapy through clinical trials is becoming a promising treatment option for some mesothelioma patients. Checkpoint inhibitor drugs, such as Keytruda, already have U.S. Food and Drug Administration (FDA) approval as first-line treatments for non-small cell lung cancer (NSCLC), edging immunotherapy drugs closer to becoming a viable second-line therapy for other thoracic cancers, including pleural mesothelioma. However, overall response to immune therapies remains relatively low. Researchers across the country are striving to enhance responsiveness to immunotherapy drugs. Leading that trend is viroimmunotherapy, or t...
Source: Asbestos and Mesothelioma News - June 6, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Biomedicines checkpoint blockade Checkpoint inhibitor drugs clinical trials for mesothelioma Dr. Alexander Dash Dr. Manish Patel FDA approval Keytruda immune response cancer immunotherapy response mesothelioma intratumoral injections k Source Type: news

Methanol from African Plants Kills Mesothelioma Cells
This study provides evidences of the cytotoxicity of the tested plant extract and highlights the good activity of Elephantopus mollis and Kalanchoe crenata,” Kuete wrote. “They deserve more exploration to develop novel cytotoxic drugs.” The post Methanol from African Plants Kills Mesothelioma Cells appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - June 2, 2017 Category: Environmental Health Authors: Matt Mauney Tags: African medicinal plants African whitewood apoptosis mesothelioma BMC Complementary and Alternative Medicine breast cancer Cameroon cancer chemotherapy colon cancer cytotoxicity against mesothelioma cells doxorubicin Dr. Victor Kuete Source Type: news

New Study Hopes to Improve Early Detection of Mesothelioma
Researchers in Germany have developed a novel blood test for mesothelioma cancer that could lead to earlier detection of the disease and a better prognosis for patients. The test involves calretinin, a blood-based protein that is overexpressed when mesothelioma tumors cells are present. The advancement stems from a study using a new enzyme-linked immunosorbent assay (ELISA) for detecting the biomarker more effectively. In the past, mesothelioma has been difficult to diagnose. It’s mostly accomplished with a combination of invasive tissue biopsies and detailed imaging tests after symptoms become obvious. A reliable bl...
Source: Asbestos and Mesothelioma News - May 30, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: biomarkers for mesothelioma calretinin assay epithelioid mesothelioma Georg Johnen Mesomark blood assay mesothelioma cancer research mesothelioma cancer treatment Source Type: news

New Bill Could Further Deregulate the Asbestos Industry
National environmental groups are banding together to fight the Regulatory Accountability Act, a bill they say would make it harder to protect consumers from dangerous substances such as asbestos. Officially known as the Regulatory Accountability Act (RAA) of 2017, it passed the U.S. House of Representatives in January and is now on the U.S. Senate floor. It combines six previously passed bills to eliminate what sponsors call “overly burdensome red tape and regulation,” while promising to hold federal agencies more accountable and create a more transparent rulemaking process. But critics claim the RAA has not...
Source: Asbestos and Mesothelioma News - May 25, 2017 Category: Environmental Health Authors: Matt Mauney Tags: asbestos ban Asbestos Ban and Phase-Out Rule asbestos legislation Corrosion Proof Fittings deregulation bills Donald Trump environmental protection agency Frank R. Lautenberg Chemical Safety for the 21st Century Act Natural Resources Defen Source Type: news

Mesothelioma Study Using Fitbit to Monitor Patient Recovery
Millions of Americans use Fitbit devices to track their daily activities, exercise and sleep patterns. But a student intern at the Pacific Heart, Lung & Blood Institute (PHLBI) in California is using the popular fitness tracker for a different purpose — as a tool to measure postsurgery recovery for mesothelioma patients. Blair Kimble, a third-year undergraduate student at UCLA, is leading the latest clinical research project for the Pacific Mesothelioma Center (PCM), a division of PHLBI. Kimble is working closely with mesothelioma surgeon Dr. Robert Cameron, the scientific advisor at PHLBI. The study investigat...
Source: Asbestos and Mesothelioma News - May 23, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Blair Kimble cancer immunotherapy research cryotherapy Dr. Raymond Wong Dr. Robert Cameron Dr. Steven Ching extrapleural pneumonectomy fitbit fitbit cancer recovery heated intraperitoneal chemotherapy Loyola Marymount University meso Source Type: news

Genetic Biomarkers Key to Future Mesothelioma Treatment
Researchers in Slovenia have developed a unique, treatment-recommendation model for mesothelioma patients based heavily upon individualized, genetic biomarkers. They believe their model will lead to better patient outcomes and significantly improve the response rate to chemotherapy, which is still less than 40 percent with mesothelioma. “This is just a start, but it’s going to be the way to go in the future, personalizing treatment,” Dr. Vita Dolzan, founder of Pharmacogenetics Laboratory at the University of Ljubljana’s Institute of Biochemistry, told Asbestos.com. “We’re excited about ...
Source: Asbestos and Mesothelioma News - May 22, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Anhovo Asbestos Valley Slovenia chemotherapy drugs for mesothelioma cisplatin CRP protein Dr. Vita Dolzan gemcitabine genetic biomarkers genetic makeup mesothelioma patients Genotyping mesothelioma treatment strategies pemetrexed p Source Type: news

Latest Keytruda Approval Promising for Mesothelioma Patients
The U.S. Food and Drug Administration (FDA) expanded its approval of pembrolizumab for first-line treatment of metastatic non-small cell lung cancer last week, moving it closer to becoming a viable treatment option for patients with pleural mesothelioma. Pembrolizumab is marketed by Merck & Co. under the brand name Keytruda. It helps the body’s immune system detect and destroy cancer cells. The FDA approved its first-line use in combination with pemetrexed and carboplatin, two chemotherapy agents used regularly for mesothelioma. Pembrolizumab, the most well-known immunotherapy drug, is being studied for use with...
Source: Asbestos and Mesothelioma News - May 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: carboplatin chemotherapy for mesothelioma Dr. Raymond Wong Dr. Tawee Tanvetyanon FDA approval Keytruda first line treatment for mesothelioma Hodgkin lymphoma jimmy carter keytruda clinical trial keytruda for mesothelioma melanoma Mer Source Type: news

Asbestos Blocked for 6th Time from Hazardous Substances List
The fight to impose tough trade restrictions on chrysotile asbestos — a toxic mineral that causes mesothelioma cancer and other serious health conditions — will have to wait at least another two years. For the sixth consecutive time, a handful of countries blocked the inclusion of the carcinogenic mineral from the Rotterdam Convention Hazardous Substances list (Annex III). Chemicals on the list are subject to restrictions that prevent the export of a product without the consent of the importing country. Representatives from 157 countries met in Geneva, Switzerland, for the eighth Conference of the Parties (CO...
Source: Asbestos and Mesothelioma News - May 17, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Andrew Dettmer Annex III asbestos ban in canada asbestos ban in united states Asbestos Disease Awareness Organization asbestos export regulations Australian Manufacturing Workers Union Belarus Chrysotile asbestos fibers Conference of the Source Type: news

Study Links Mesothelioma in Women to Cloth Dolls in Factory
A rising number of women are diagnosed with mesothelioma cancer each year. Researchers in Italy are the latest to study this growing trend and show that asbestos exposure — the main cause of mesothelioma — doesn’t only affect men working certain blue-collar jobs. The report, published in the Italian medical journal La Medicina del Lavoro in April, analyzes possible asbestos exposure in a cloth doll factory. Using data from the Province of Brescia Mesothelioma Registry, researchers found three cases of pleural mesothelioma cancer diagnosed in young women who had worked for two doll manufacturing companies....
Source: Asbestos and Mesothelioma News - May 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: asbestos cloth doll factory asbestos doll manufacturing environmental asbestos exposure La Medicina del Lavoro mesothelioma cloth doll workers mesothelioma in Italy occupational asbestos exposure Pietrogino Barbieri Province of Brescia Mes Source Type: news

Multiple Sclerosis Drug Effectively Stops Mesothelioma Cells
Research from the University of Hawaii Cancer Center shows an immune suppression drug already used to treat multiple sclerosis could become an effective tool against malignant mesothelioma. The drug, fingolimod (FTY720), showed an ability to shrink mesothelioma tumors cells in the laboratory and in animal models without causing substantial side effects. Fingolimod, which is derived from the fungus isaria sinclairii, also is being studied for potential use with cervical, breast, lung and prostate cancers. This was the first study of its effectiveness with mesothelioma. The Journal of Translational Medicine published the res...
Source: Asbestos and Mesothelioma News - May 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: anti-cancer effect on mesothelioma cells Dr. Haining Yang fingolimod mesothelioma FTY720 immune suppression drugs isaria sinclairii Journal of Translational Medicine mesothelioma life expectancy multiple sclerosis drugs Repurposing drugs Source Type: news

New VA Health Care Bill Can Help Mesothelioma Patients
A recent extension and reform of the Veterans Choice Program could allow for better access to care for veterans diagnosed with rare cancers such as mesothelioma. President Donald Trump signed the Veterans Choice Program Extension and Improvement Act (S.544) into law on April 18. The bill amends the Veterans Access, Choice, and Accountability Act of 2014, eliminating the Aug. 7, 2017, expiration date and allowing the program to operate until the remaining $950 million in the Veterans Choice Fund is expended. Under the new law, military veterans can continue receiving health care in the private sector when care isn’...
Source: Asbestos and Mesothelioma News - May 10, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Aaron Munz David Shuklin Donald Trump mesothelioma life expectancy military veterans asbestos exposure pending VA claims President Barack Obama private health care for veterans Trump executive orders VA accountability and whistleblower p Source Type: news

FDA Cracks Down on Fake Mesothelioma Treatments
Stories abound of a “cancer-curing” tea from the forests of Canada. Herbal blends claim to “attack cancer at the DNA level.” For many years, mesothelioma patients have turned to alternative medicines like these as treatment options for the rare asbestos-related cancer. Sometimes these options are a last resort, after traditional treatments fail. They may be used in conjunction with standard treatment (complementary medicine) or on their own as the main approach. But the U.S. Food and Drug Administration (FDA) recently issued warning letters to companies that manufacture or market products claimin...
Source: Asbestos and Mesothelioma News - May 2, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Alternative medicine Asparagus Extract BioStar Technology International Budwig Protocol cancer supplements cannabis oil cancer CellAssure Centers for Disease Control and Prevention Chelated Boron Circulatory Detox & Support Syrup compl Source Type: news

New Mesothelioma Clinical Trial for Pleural, Peritoneal Patients
Pleural and peritoneal mesothelioma patients are eligible for a new clinical trial that combines the latest antibody-drug conjugate with standard-of-care chemotherapy at the Ochsner Medical Center in New Orleans. The drug, anetumab ravtansine (BAY 94-9343), is the highly touted conjugate that mixes immunotherapy with cytotoxic therapy and targets mesothelin, the tumor surface protein found in 85-90 percent of mesothelioma cancer patients. The Ochsner trial, which is currently recruiting participants, is the first time researchers will administer anetumab ravtansine in a first-line setting for mesothelioma. “It’...
Source: Asbestos and Mesothelioma News - April 28, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: anetumab ravtansine mesothelioma chemotherapy mesothelioma clinical trial new mesothelioma treatment ochsner clinical trial Source Type: news

Moffitt Opens Mesothelioma Study for Rare Cancer Subtypes
The Moffitt Cancer Center in Tampa has opened a mesothelioma clinical trial involving an anti-cancer enzyme drug showing unprecedented success with the most difficult disease subtypes. Patients with sarcomatoid and biphasic histology — the most treatment-resistant subtypes of mesothelioma — can now enroll in a phase 2/3 clinical trial involving the effectiveness of ADI-PEG 20 (pegylated arginine deiminase) in combination with standard chemotherapy. Thoracic surgeon Dr. Jacques Fontaine, director of the Mesothelioma Research and Treatment Center at Moffitt, told Asbestos.com that he and fellow investigators are ...
Source: Asbestos and Mesothelioma News - April 25, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: doctor jacques fontaine improving mesothelioma prognosis mesothelioma chemotherapy with cisplatin mesothelioma clinical trial mesothelioma treatments moffitt cancer center Source Type: news

Select Mesothelioma Patients Still Benefit from EPP Surgery
The controversial extrapleural pneumonectomy (EPP) surgery should remain a viable option for select patients with malignant mesothelioma, despite a growing reluctance today among thoracic surgeons to recommend the procedure. When combined with intensity modulated radiation therapy (IMRT), the EPP still can benefit some patients and improve survival times significantly, according to a recent study at the Baylor Scott & White Medical Center in Temple, Texas. The retrospective look at 18 patients who underwent the EPP/IMRT combination found an average, overall survival rate of 38.2 months and a median relapse-free surviva...
Source: Asbestos and Mesothelioma News - April 17, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: extrapleural pneumonectomy intensity modulated radiation therapy mesothelioma life expectancy mesothelioma surgery mesothelioma survival rates Source Type: news

Asbestos Contaminates Canadian University Labs
Fear and frustration best describes emotions felt by University of Toronto faculty and students after they say administration delayed notification that asbestos contaminated some of the university’s science labs. “The emotional experience is really devastating,” said physiology and medicine professor Adria Giacca in an interview with CBC News. Another professor, who didn’t want to be identified, told the Globe and Mail: “I’ve lost confidence, and my lab people have lost confidence…[It] perpetuates fear whenever you see dust, you now worry. Am I going to get cancer 20 years from no...
Source: Asbestos and Mesothelioma News - April 12, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos ban in canada asbestos exposure in canada asbestos exposure in schools asbestos in canada Source Type: news

Shorter Mesothelioma Survival Linked to High Platelet Count
A disorder that forces the body to overproduce platelets is now linked to worsening the prognosis of peritoneal mesothelioma patients, according to researchers at the University of Maryland School of Medicine. Previous clinical trials associated a high platelet count, also known as thrombocytosis, with poor outcomes for various malignancies. However, the recent study at The Greenebaum Comprehensive Cancer Center in Baltimore is the first to evaluate the clinical significance of thrombocytosis with mesothelioma cancer. The study, published March 21 in the Annals of Surgical Oncology, analyzed overall survival for peritoneal...
Source: Asbestos and Mesothelioma News - April 3, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy for mesothelioma heated intraperitoneal chemotherapy hyperthermic intraperitoneal chemotherapy mesothelioma survival peritoneal mesothelioma survival platelet count for mesothelioma thrombocytosis for mesothelioma Source Type: news

Keytruda Proves Effectiveness with Mesothelioma
This study provides evidence that some patients [with mesothelioma] can have long-term disease control with this drug, which we haven’t seen before,” Alley said in a press release. “This drug appears to be well tolerated.” Real Need for Second-Line Therapy Standard first-line therapy for mesothelioma includes a combination of chemotherapy, radiation and surgery, but it remains relatively ineffective as a long-term solution. Alley believes pembrolizumab, classified as a checkpoint inhibitor drug, can provide a needed advancement in treatment. Checkpoint inhibitors allow the immune system to fight off...
Source: Asbestos and Mesothelioma News - March 31, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center checkpoint inhibitors Dr. Evan Alley keytruda keytruda clinical trials keytruda for mesothelioma Merck & Co. PD-L1 proteins pembrolizumab Pembrolizumab mesothelioma Penn Medicine Penn Presbyterian Medical Cente Source Type: news

Nutritional Index Helps Predict Mesothelioma Prognosis
A recent study further expands on the important role nutrition plays in how well mesothelioma patients will respond to treatments. Researchers in Japan evaluated the Controlling Nutritional Status (CONUT) score — an index developed as a screening tool for early detection of poor nutritional status — as a predictive marker for mesothelioma prognosis. CONUT has been used to predict the prognosis of other cancers, but never for malignant pleural mesothelioma (MPM), a rare and aggressive cancer caused by exposure to asbestos. “The CONUT score was an independent predictor of a poor prognosis in the patients...
Source: Asbestos and Mesothelioma News - March 29, 2017 Category: Environmental Health Authors: Matt Mauney Tags: bap1 gene mutation Controlling Nutritional Status score CONUT score malignant pleural mesothelioma mesothelioma malnutrition mesothelioma nutrition Mesothelioma prognosis mesothelioma stages nutrition mesothelioma survival Osaka City Uni Source Type: news

Mesothelioma Researcher Questions Benefits of EPP Surgery
Former thoracic surgeon Dr. Tom Treasure at University College London was never a believer in the aggressive extrapleural pneumonectomy (EPP) surgery still performed today for patients with malignant pleural mesothelioma. As a researcher now, he dismisses the potential benefit with even more conviction. “Doing the EPP can’t be justified anymore,” Treasure told Asbestos.com. “One more [of these surgeries] is one too many. I feel more confident about that now than ever before. We really have to spare people from the treatments that don’t help.” In recent years, the mesothelioma community h...
Source: Asbestos and Mesothelioma News - March 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: doctor david sugarbaker Doctor Tom Treasure EPP surgery for mesothelioma lung institute at baylor mesothelioma surgery mesothelioma treatment pleurectomy decortication Source Type: news

Veterans with Mesothelioma Benefit from Telephone Triage
U.S. military veterans with malignant pleural mesothelioma can rely on the VA Boston Healthcare System’s national phone triage for improved access to specialized surgical advice and better treatment recommendations, according to a retrospective study. Thoracic surgeons Drs. Abraham Lebenthal and Jeff Siegert helped establish the open access telephone triage in 2011, shortening the average time between a veteran’s initial phone screen and face-to-face surgical consultation to 14 days. Many veterans facing a potential diagnosis of mesothelioma must navigate the historically mismanaged federal agency to get the tr...
Source: Asbestos and Mesothelioma News - March 20, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Boston VA Brigham and Women’s Hospital Dr. Abraham Lebenthal Dr. Jeff Siegert malignant pleural mesothelioma military veterans mesothelioma Telephone triage VA benefits Source Type: news

Trump Will Likely Support Asbestos FACT Act
A House Judiciary Committee approved the Furthering Claims Transparency Act of 2017, one of numerous iterations of the legislation since 2004, which asbestos foes claim will hurt those seeking much-deserved compensation. Repeatedly stalled in the legislature in previous years with a promised veto from President Barack Obama, supporters are hopeful President Donald Trump will support the bill as part of a reform package. Republican sponsor U.S. Rep. Blake Farenthold of Texas introduced the bill in February. Opponents Fear Asbestos Victims’ Privacy Is at Stake Linda Reinstein, president of the Asbestos Disease Awarenes...
Source: Asbestos and Mesothelioma News - March 7, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: Asbestos Disease Awareness Organization asbestos trust claims asbestos trusts FACT Act filing an asbestos trust claim Furthering Claims Transparency Act of 2017 Linda Reinstein trump asbestos U.S. Rep. Blake Farenthold Source Type: news

Hospice Program Eases Breathing for Mesothelioma Patients
Dr. Michael Shapiro has developed a program that should make breathing easier for a patient with malignant pleural mesothelioma. He equates his breathing program to teaching an elite athlete how to better utilize his lung capacity by using similar concepts that assist people struggling with serious respiratory issues in hospice care. “We’re not reinventing the wheel, by any stretch of the imagination,” Shapiro told Asbestos.com. “But there are ways to teach people, at all levels, to breath more efficiently. Our goal is to help provide a better quality of life for a patient.” Shapiro is the chi...
Source: Asbestos and Mesothelioma News - March 3, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: breathing exercises for mesothelioma dr. michael shapiro hospice care for mesothelioma mesothelioma treatment Source Type: news

Firefighters with Mesothelioma Protected by New Ohio Law
A new piece of legislation extends workers’ compensation rights for Ohio firefighters to include occupational cancers such as mesothelioma. Ohio Gov. John Kasich signed the Michael Louis Palumbo Jr. Act into law Jan. 4. The bill essentially classifies cancer as an occupational disease for firefighters, allowing firefighters who have cancer to file claims with the Ohio Bureau of Workers’ Compensation. More than 30 states already have similar laws. Doug Stern of the Ohio Association of Professional Firefighters (OAPFF) said the legislation is based on scientific research that links asbestos-related cancers, suc...
Source: Asbestos and Mesothelioma News - January 30, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: firefighters asbestos exposure firefighters with mesothelioma governor john kasich occupational mesothelioma cancer ohio law protects firefighters Source Type: news

$80M Asbestos Settlement Reached in Kansas City
An $80 million asbestos settlement involving two former Jackson County courthouse employees led to Missouri’s largest medical monitoring fund established in an asbestos case. The class-action asbestos lawsuit settled more than 30 years after a renovation exposed thousands of government workers to deadly asbestos fibers. Jackson County and Kansas City-based U.S. Engineering, the firm responsible for the asbestos removal, agreed to settle the case in October 2016, just a week prior to the opening trial date. An estimated 7,500 people — former courthouse employees, jurors, attorneys and jail inmates — could...
Source: Asbestos and Mesothelioma News - January 25, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos in kansas city courthouse asbestos lawsuit asbestos litigation in missouri asbestos settlement kansas city asbestos lawsuit kansas city asbestos settlement mesothelioma lawsuit mesothelioma lawyer in missouri Source Type: news